

ORGAN AND TISSUE TRANSPLANTATION AND ALTERNATIVES



HLC012F
March 2015

Peggy Lehr
Project Analyst

ISBN: 1-62296-059-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
REASONS FOR DOING THE STUDY	2
STUDY GOALS AND OBJECTIVES	2
SCOPE OF REPORT	3
METHODOLOGIES AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
COST OF CARE	7
GLOBAL MARKET	7
SOLID ORGAN PRESERVATION	8
IMMUNOSUPPRESSION	8
DONATION	8
SOFT TISSUE MARKET	9
ORGAN ALTERNATIVES	9
GLOBAL MARKET PROJECTIONS	9
<i>SUMMARY TABLE PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND DEVICES, THROUGH 2020 (\$ MILLIONS)</i>	9
<i>SUMMARY FIGURE PROJECTED GLOBAL MARKET SHARE OF TRANSPLANTATION PRODUCTS AND DEVICES, 2015 AND 2020 (%)</i>	10
CHAPTER 3 INDUSTRY OVERVIEW	12
HISTORY OF TRANSPLANTATION	12
<i>TABLE 1 TIMELINE OF ORGAN TRANSPLANTATION HISTORY, 1900-2012</i>	12
INDUSTRY ACQUISITIONS	14
<i>TABLE 2 SELECTED TRANSPLANT INDUSTRY ACQUISITIONS, 2010-EARLY 2015 (\$ MILLIONS)</i>	14
NECESSARY COMPONENTS TO ORGAN AND TISSUE TRANSPLANTATION	15
TISSUE TYPING	15
PRESERVATION	15
Tissue Preservation	15
IMMUNOSUPPRESSION	16
Newer Immunosuppressive Drugs	16
POSTOPERATIVE INFECTION CONTROL	17
OVERVIEW OF THE DONATION PROCESS	17
BLACK MARKET DONORS	17
THE TRANSPLANTATION PROCESS	18
PREPARATION	18
The Role of the Organ Procurement Organization	18
SURGERY	19
RECUPERATION	19
MAINTENANCE	20
SOLID ORGANS	20

TOPIC	PAGE NO.
COST OF SOLID ORGAN TRANSPLANTATION IN THE U.S.	20
<i>TABLE 3 U.S. ORGAN/TISSUE TRANSPLANTS: AVERAGE FIRST YEAR COST, ESTIMATED NUMBER OF PROCEDURES, AND VALUE BY TYPE OF ORGAN TRANSPLANT, 2011</i>	20
KIDNEY TRANSPLANTS IN THE U.S.	21
Living Donor Efforts	21
Necessary Inputs for Successful Kidney Transplantation	22
LIVER TRANSPLANTATION IN THE U.S.	22
Promising Treatments	22
Necessary Inputs for Successful Liver Transplantation	22
HEART TRANSPLANTS IN THE U.S.	22
Necessary Inputs for Successful Heart Transplantation	22
INTESTINE TRANSPLANTATION IN THE U.S.	23
Necessary Inputs for Successful Intestine Transplantation	23
PANCREAS TRANSPLANTATION IN THE U.S.	23
Necessary Inputs for Successful Pancreas Transplantation	23
TISSUE TRANSPLANTATION IN THE U.S.	24
TRANSPLANTATION TRENDS OUTSIDE THE U.S.	24
ORGAN DONATION IN EUROPE	24
<i>TABLE 4 ORGAN DONATIONS IN EUROPE, BY TYPE, 2012-2013</i>	24
Standards in Europe	25
Transplant Organizations in the EU	25
JAPANESE ORGAN TRANSPLANT CRITERIA	26
Tradition and Beliefs	26
Brain Death in Japan	27
Three Key Elements of Conventional Death in Japan	27
TRENDS IN LIVING AND CADAVERIC DONATIONS OUTSIDE THE U.S.	27
GLOBAL SOLID ORGAN TRANSPLANTATION	27
<i>TABLE 5 GLOBAL ACTIVITY IN ORGAN TRANSPLANTATION, 2012</i>	27
KIDNEY DONATIONS	28
LIVER DONATIONS	28
LIMITED ORGAN SUPPLY CURTAILS TRANSPLANTATIONS	28
LIVING DONOR PROGRAMS	28
KEY FACTORS IN INDUSTRY GROWTH	29
REDUCING DEMAND	29
INCREASING PATIENT SURVIVAL RATES	29
<i>TABLE 6 U.S. GRAFT SURVIVAL RATES, BY ORGAN AND YEARS (%)</i>	29
DEVELOPING ORGAN SUBSTITUTES	30
Organs from Animals: Xenotransplantation	30
Emotional/Ethical Implications of Xenotransplantation	30
Organ Primordia	30
ARTIFICIAL ORGANS	31
KEY FACTORS INHIBITING GROWTH	31
LACK OF DONORS	31
ALTERNATIVE THERAPIES	31
PHARMACEUTICAL TREATMENTS	32
CULTURAL STIGMAS	32
Opt-in Consent and Presumed Consent	32

TOPIC	PAGE NO.
Anatomical Intent and Payment for Organs in the U.S.	32
REGULATIONS AND REIMBURSEMENT	33
REGULATIONS IN THE U.S.	33
U.S. FEDERAL REGULATION OF HUMAN TISSUE	34
HISTORY OF REGULATION IN THE U.S.	34
REGULATIONS OUTSIDE THE U.S.	34
TRANSPLANT "TOURISM"	35
REIMBURSEMENT IN THE U.S.	35
ORGAN ACQUISITION COSTS	35
REIMBURSEMENT FOR HOSPITAL COSTS	36
REIMBURSEMENT FOR PHYSICIAN SERVICES	36
REIMBURSEMENT FOR IMMUNOSUPPRESSANTS IN THE U.S.	36
<i>TABLE 7 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*</i>	37
<i>TABLE 8 OVERVIEW OF MEDICARE IMMUNOSUPPRESSIVE DRUG COVERAGE</i>	38
REIMBURSEMENT OUTSIDE THE U.S.	38
TREATMENT IN EU COUNTRIES	39
CHAPTER 4 TISSUE TYPING TECHNOLOGIES	41
ROLE OF TISSUE TYPING IN TRANSPLANTATION	41
TISSUE TYPING TECHNOLOGIES	41
<i>TABLE 9 TISSUE TYPING TECHNOLOGIES</i>	42
HLA ANALYSIS METHODS	42
SEQUENCE-SPECIFIC TYPING	42
Panel Reactive Antibodies (PRA)	43
Sequence-Specific Primer (SSP)	43
Sequence-Specific Oligonucleotide Probes (SSOP)	43
REFERENCE STRAND-BASED MEDIATED CONFORMATION ANALYSIS (RSCA)	44
GLOBAL TISSUE TYPING MARKET	44
<i>TABLE 10 PROJECTED GLOBAL MARKET FOR TISSUE TYPING, THROUGH 2020 (\$ MILLIONS)</i>	44
COMMERCIALIZATION OPPORTUNITIES IN TISSUE TYPING	44
MARKET LEADERS	45
<i>FIGURE 1 GLOBAL MARKET SHARES IN TISSUE TYPING TECHNOLOGIES BY MARKET LEADER, 2014 (%)</i>	45
REGIONAL ANALYSIS	46
<i>TABLE 11 PROJECTED GLOBAL TISSUE TYPING MARKET, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	46
CHAPTER 5 SOLID ORGAN PROCUREMENT AND PRESERVATION	48
DEFINITION OF BRAIN DEATH	48
ORGANS OBTAINED FOR TRANSPLANT	48
INCREASING SUPPLY IN THE U.S.	49
THE TRANSPLANT GROWTH AND MANAGEMENT COLLABORATIVE	49
SUPPLY MANAGEMENT	49
REDUCING WASTE AND REJECTION	49
FIGHTING REJECTION	49
<i>TABLE 12 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2007-2013</i>	50

TOPIC	PAGE NO.
INCREASING THE HARVEST	50
<i>TABLE 13 PERCENT OF U.S. ORGAN DISCARDS, BY TYPE, 2012 (%)</i>	50
NON-BEATING HEART DONORS	51
LESS WASTE	51
ORGAN PROCUREMENT OUTSIDE THE U.S.	51
MANAGEMENT OF DONATED ORGANS IN THE EU	51
CHINA	52
JAPAN	52
ALLOCATION CRITERIA IN THE U.S.	52
<i>TABLE 14 MEDIAN U.S. WAITLIST TIME FOR POTENTIAL RECIPIENTS, BY ORGAN AND NUMBER OF MONTHS, 2008 (NO. OF MONTHS)</i>	53
MELD/PELD SYSTEM	53
ALLOCATION CRITERIA IN THE EU	54
MELD/PELD IN THE U.K.	54
SOLID ORGAN PRESERVATION	54
<i>TABLE 15 COLD ISCHEMIA TIME FOR TRANSPLANTED ORGANS (HOURS)</i>	55
GLOBAL MARKET FOR ORGAN PRESERVATION METHODS	55
<i>TABLE 16 PROJECTED GLOBAL MARKET FOR ORGAN PRESERVATION METHODS, THROUGH 2020 (\$ MILLIONS)</i>	55
SIMPLE STATIC COLD STORAGE	55
<i>TABLE 17 OPTIMAL PRESERVATION SOLUTION DESIGN</i>	56
Rinse and Preservation Solutions	57
<i>TABLE 18 MAJOR ORGAN PRESERVATION SOLUTIONS</i>	57
KIDNEY COLD-STORAGE METHODS STUDY	58
TYPES OF COLD STORAGE SOLUTIONS	58
Celsior	58
Euro Collins Solution	58
Custodiol	59
Hypothermosol FRS	59
Perfadex	59
UW Solution	59
KPS-1 Kidney Perfusion Solution	59
Lifor	60
MARKET FOR PRESERVATION SOLUTIONS	60
<i>TABLE 19 PROJECTED GLOBAL MARKET FOR SOLID ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORTH COCKTAIL) BY GEOGRAPHIC REGION, THROUGH 2020 (\$ MILLIONS)</i>	60
GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS	61
<i>FIGURE 2 GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS 2013 (%)</i>	61
MACHINE PERFUSION	61
EARLY MACHINE PERFUSION	61
CURRENT MACHINE PERFUSION	62
<i>TABLE 20 ADVANTAGES AND DISADVANTAGES OF MACHINE PERFUSION</i>	62
MARKET FOR MACHINE PERFUSION/ORGAN TRANSPORT SYSTEMS	63
<i>TABLE 21 PROJECTED GLOBAL MARKET FOR MACHINE PERFUSION /ORGAN TRANSPORT SYSTEMS, THROUGH 2020 (\$ MILLIONS)</i>	63
ORGAN TRANSPORT AND PERFUSION SYSTEMS	63
Sherpa Perfusion Systems	63

TOPIC	PAGE NO.
Waves Renal Perfusion	63
LifePort	64
KidneyAssist	64
LifeCradle	64
Organ Care System	64
PRESERVATION SOLUTIONS IN DEVELOPMENT	64
KYOTO UNIVERSITY SOLUTION	64
IGL-1 SOLUTION	65
SOMAH SOLUTION	66
VASOWAVE	66
CHAPTER 6 TISSUE PRODUCTS	68
<i>TABLE 22 PROJECTED GLOBAL TISSUE GRAFTING MARKET, BY TISSUE TYPE THROUGH 2020 (\$ MILLIONS)</i>	68
GLOBAL TISSUE MARKET, BY REGION	68
<i>TABLE 23 PROJECTED GROWTH IN TISSUE MARKET REVENUES, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	69
<i>FIGURE 3 GLOBAL TISSUE MARKET SHARES BY REGION, 2015 AND 2020 (%)</i>	69
SOFT TISSUE REPAIR AND REPLACEMENT	70
CARTILAGE REPAIR AND REPLACEMENT	70
OTHER SOFT TISSUE REPAIR AND REPLACEMENT	70
<i>TABLE 24 CARTILAGE AND SOFT TISSUE BIOLOGICS AND BIOMATERIALS</i>	71
PROJECTED GLOBAL SOFT TISSUE MARKET	72
<i>TABLE 25 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, THROUGH 2020 (\$ MILLIONS)</i>	72
PROJECTED GLOBAL SOFT TISSUE MARKET, BY REGION	72
<i>TABLE 26 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	72
<i>FIGURE 4 GLOBAL SOFT TISSUE MARKET, BY REGION, IN 2015 AND 2020 (%)</i>	73
HEART VALVES	74
MECHANICAL	74
BIOLOGICAL/TISSUE	74
HOMOGRAFT	74
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)	74
GROWTH IN THE HEART VALVE MARKET	75
<i>TABLE 27 GLOBAL HEART VALVE MARKET, THROUGH 2020 (\$ MILLIONS)</i>	75
HEART VALVE MARKET LEADERS	76
<i>FIGURE 5 LEADING HEART VALVE SUPPLIERS, 2014 (%)</i>	76
GLOBAL HEART VALVE MARKET, BY REGION	77
<i>TABLE 28 PROJECTED GLOBAL MARKET FOR HEART VALVES, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	77
HEART VALVE MARKET IN THE FUTURE	77
CORNEA	77
CORNEAL TRANSPLANTS IN THE U.S.	78
GLOBAL CORNEAL TRANSPLANT MARKET	78
<i>TABLE 29 PROJECTED GLOBAL GROWTH OF CORNEAL TRANSPLANT MARKET, THROUGH 2020* (\$ MILLIONS)</i>	78
BLOOD STEM CELLS	79
HISTORY	79

TOPIC	PAGE NO.
First Successful Transplant	79
Donor Registries	80
GLOBAL STEM CELL TRANSPLANT ACTIVITY	80
INDICATIONS FOR STEM CELL TRANSPLANTS	81
REJECTION	81
TYPES OF STEM CELLS	82
Bone Marrow	82
Peripheral Blood	82
Umbilical Cord Blood	83
GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION	83
<i>TABLE 30 PROJECTED GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION, THROUGH 2020 (\$ MILLIONS)</i>	84
WORLDWIDE INCIDENCE OF PROCEDURES	84
THE ORTHOBIOLOGICS MARKET	85
<i>TABLE 31 PROJECTED GLOBAL MARKET FOR ORTHOBIOLOGICAL PRODUCTS, THROUGH 2020* (\$ MILLIONS)</i>	85
BASE TISSUE	85
BONE PUTTY/DEMINERALIZED BONE MATRIX (DBM) PRODUCTS	85
MACHINED IMPLANTS	86
<i>TABLE 32 HUMAN BONE PRODUCTS AND MARKETERS</i>	86
SYNTHETIC BONE REPLACEMENTS	87
<i>TABLE 33 SYNTHETIC BONE-REPLACEMENT PRODUCTS AND MARKETERS</i>	88
SKIN GRAFTS	88
APPLICATIONS	89
MARKET FOR SKIN GRAFTS	89
<i>TABLE 34 PROJECTED GLOBAL GROWTH OF SKIN GRAFTS, THROUGH 2020 (\$ MILLIONS)</i>	89
VASCULAR TISSUE TRANSPLANTATION	90
PRODUCTS	90
GLOBAL MARKET FOR VASCULAR TISSUE	90
<i>TABLE 35 PROJECTED GLOBAL VASCULAR TISSUE TRANSPLANTATION MARKET, THROUGH 2020 (\$ MILLIONS)</i>	91
CHAPTER 7 IMMUNOSUPPRESSANTS, ANTI-INFECTIVES AND POST-TRANSPLANT MONITORING	93
TOLERANCE OF TRANSPLANTED ORGANS	93
ANTISENSE THERAPY	93
COSTIMULATION	94
CHIMERISM	94
COMMON ANTI-REJECTION DRUG PROTOCOLS	94
TYPES OF IMMUNOSUPPRESSANTS	95
<i>TABLE 36 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS USED IN TRANSPLANTS, BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	95
<i>FIGURE 6 PROJECTED GLOBAL MARKET SHARES OF IMMUNOSUPPRESSIVES BY TYPE, THROUGH 2020 (%)</i>	96
<i>TABLE 37 IMMUNOSUPPRESSANT DRUGS APPROVED IN THE U.S., THE EU, AND JAPAN, THROUGH 2014</i>	97
<i>TABLE 38 IMMUNOSUPPRESSANTS BY DRUG CLASS, GENERIC NAME, BRAND NAME, AND MANUFACTURER</i>	97

TOPIC	PAGE NO.
CALCINEURIN INHIBITORS	98
CYCLOSPORINE	99
Generic Cyclosporine	99
TACROLIMUS	99
<i>TABLE 39 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 (\$ MILLIONS)</i>	99
ANTI-PROLIFERATIVE AGENTS	100
AZATHIOPRINE	100
MYCOPHENOLATE MOFETIL	100
MYCOPHENOLATE SODIUM	100
<i>TABLE 40 GLOBAL MARKET FOR ANTI-PROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 (\$ MILLIONS)</i>	101
M-TOR INHIBITORS	101
SIROLIMUS	101
TEMSIROLIMUS	102
EVEROLIMUS (CERTICAN/ZORTRESS)	102
<i>TABLE 41 PROJECTED GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 (\$ MILLIONS)</i>	102
MONOCLONAL AND POLYCLONAL ANTIBODY PRODUCTS	102
<i>TABLE 42 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION</i>	103
POLYCLONAL ANTIBODY PRODUCTS	103
Thymoglobulin	103
Atgam	104
<i>TABLE 43 PROJECTED GLOBAL MARKET FOR POLYCLONAL ANTIBODY PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	104
MONOCLONAL ANTIBODY PRODUCTS	104
Off-label Medications	104
Rituximab	104
T-CELL COSTIMULATION BLOCKER	105
<i>TABLE 44 PROJECTED GLOBAL MARKET FOR T-CELL COSTIMULATION BLOCKERS, THROUGH 2020 (\$ MILLIONS)</i>	105
TREATMENTS BY STAGE OF PROCEDURE	105
INDUCTION THERAPY	106
Disadvantages of Induction Therapy	106
Standard Treatments	106
<i>TABLE 45 IMMUNOSUPPRESSANT USE FOR INDUCTION BY ORGAN IN U.S., 2012* (%)</i>	107
MAINTENANCE THERAPY	107
<i>TABLE 46 IMMUNOSUPPRESSANT USE FOR MAINTENANCE (UP TO 2 YEARS POST-TRANSPLANT) BY ORGAN, 2010* (%)</i>	108
IMMUNOSUPPRESSANT USE IN PEDIATRIC TRANSPLANTATION	109
ADVANCES IN POST-OPERATIVE DESENSITIZATION	109
GLOBAL IMMUNOSUPPRESSANT MARKET	110
<i>TABLE 47 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	110
<i>FIGURE 7 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, 2015 AND 2020 (%)</i>	110
ANTI-INFECTIVES AND POST-TRANSPLANT MONITORING IN ORGAN AND TISSUE TRANSPLANTATION	111

TOPIC	PAGE NO.
ANTI-INFECTIVES AND IMMUNOSUPPRESSANTS	112
<i>TABLE 48 COMMON ANTI-INFECTIVE AND IMMUNOSUPPRESSANT AGENTS AND INTERACTIONS, 2012*</i>	112
Market for Anti-infectives in transplantation	114
<i>TABLE 49 POST-TRANSPLANT INFECTIONS BY TYPE OF TRANSPLANT, WITH COMMON TIME FRAMES FOR INFECTION</i>	114
POST-TRANSPLANT MONITORING	116
<i>TABLE 50 RECOMMENDED POST-TRANSPLANT CARE, 2012</i>	116
CHAPTER 8 ALTERNATIVE DEVICES AND TECHNOLOGIES	120
<i>TABLE 51 PROJECTED GLOBAL MARKET FOR TRANSPLANTATION ALTERNATIVE DEVICES, THROUGH 2020 (\$ MILLIONS)</i>	121
ALTERNATIVES TO HEART TRANSPLANTATION	121
MEDICAL	121
SURGICAL	121
Cardiac Support Devices	121
MECHANICAL	122
Total Artificial Heart	122
Ventricular Assist Devices	122
Generations of Designs	122
<i>TABLE 52 GLOBAL MARKET FOR ARTIFICIAL HEART DEVICES, THROUGH 2020 (\$ MILLIONS)</i>	123
TOTAL ARTIFICIAL HEARTS	123
<i>TABLE 53 GLOBAL MARKET FOR TOTAL ARTIFICIAL HEARTS, THROUGH 2020 (\$ MILLIONS)</i>	124
VENTRICULAR ASSIST DEVICES	124
Regeneration Instead of Replacement	124
<i>TABLE 54 GLOBAL MARKET FOR VADS, THROUGH 2020 (\$ MILLIONS)</i>	124
VAD as Destination Therapy	124
VAD Development Outside the U.S.	125
OPPORTUNITIES IN THE ORTHOPEDIC DEVICE MARKET	125
<i>TABLE 55 SELECTED GLOBAL COMMERCIAL OPPORTUNITIES FOR NEW DEVICES IN THE FUTURE</i>	125
<i>TABLE 56 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC DEVICES USED IN TRANSPLANTATION, THROUGH 2020 (\$ MILLIONS)</i>	126
<i>FIGURE 8 GLOBAL MARKET FOR ORTHOPEDIC DEVICES, BY TYPE, 2015 AND 2020 (%)</i>	126
MARKET LEADERS IN ORTHOPEDIC REPLACEMENTS	127
<i>FIGURE 9 ORTHOPEDIC REPLACEMENT DEVICE MARKET, BY COMPANY MARKET SHARE, 2014 (%)</i>	128
HIP	128
COSTS OF HIP REPLACEMENT SURGERIES	129
ALTERNATIVES TO HIP REPLACEMENT/RECONSTRUCTION	129
<i>TABLE 57 PROJECTED GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	129
KNEE	129
<i>TABLE 58 PROJECTED GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	130
SPINE	130

TOPIC	PAGE NO.
<i>TABLE 59 PROJECTED GLOBAL MARKET FOR SPINAL RECONSTRUCTIVE PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	131
<i>FIGURE 10 GLOBAL MARKET SHARES OF THE SPINAL RECONSTRUCTION MARKET BY COMPANY, 2013 (%)</i>	131
EXTREMITIES	132
MARKET DRIVERS	132
<i>TABLE 60 PROJECTED GLOBAL MARKET FOR EXTREMITY REPAIR/REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	132
ALTERNATIVES TO CORNEAL TRANSPLANTATION	132
SURGICAL	133
<i>TABLE 61 THERAPEUTIC INDICATIONS FOR PTK</i>	133
Cellular Retinal Transplants	133
Electronic Implants	134
ALTERNATIVES TO INTESTINAL TRANSPLANTATION	134
MEDICAL	134
ALTERNATIVES TO PANCREAS TRANSPLANTATION	135
SURGICAL	135
Islet Cell Transplantation	135
BIOARTIFICIAL PANCREAS	135
ALTERNATIVES TO LIVER TRANSPLANTATION	136
<i>TABLE 62 INDICATIONS FOR BIOARTIFICIAL LIVER TRANSPLANTATION</i>	137
ALTERNATIVES TO VASCULAR TRANSPLANTATION	137
TISSUE ENGINEERING OF VASCULAR GRAFTS	137
GENE THERAPY	138
REGIONAL ANALYSIS	138
<i>TABLE 63 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC AND CARDIAC ALTERNATIVE THERAPIES, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	139
<i>FIGURE 11 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC IMPLANT PRODUCTS, BY REGION, 2015 AND 2020 (%)</i>	139
CHAPTER 9 EMERGING PROCEDURES AND PRODUCTS IN DEVELOPMENT	142
ORGAN PRESERVATION SOLUTIONS IN DEVELOPMENT	142
KYOTO UNIVERSITY SOLUTION	142
IGL-1 SOLUTION	143
SOMAH SOLUTION	143
VASOWAVE	144
ISOGARCINOL	144
REGENERATIVE MEDICINE	144
APPLICATIONS IN LIVER TRANSPLANTS	144
ISLET CELL TRANSPLANTATION	144
CELLULAR THERAPIES	145
<i>TABLE 64 TYPES OF REGENERATIVE CELLULAR THERAPIES</i>	145
KIDNEY TRANSPLANT	145
New Molecule for Stable Immunological Tolerance after Kidney Transplantation	145
Veloxis Pharmaceuticals	146
Alexion	146
CYTOMEGALOVIRUS TREATMENTS	146
Astellas Pharmaceuticals	146

TOPIC	PAGE NO.
CORNEAL TRANSPLANTS	146
Stem Cells and Bioengineering	146
STEM CELL RESEARCH	147
STEM CELL RESEARCH FUNDING IN THE U.S,	147
ADVANCES IN CARDIOVASCULAR TREATMENTS	147
FIBROBLAST GROWTH FACTORS	147
CARDIOVASCULAR BIOTHERAPEUTIC INC.	148
IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT	149
<i>TABLE 65 SELECTED IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT, 2015</i>	149
PHARMACEUTICAL PIPELINE DEVELOPMENT	149
<i>TABLE 66 PHARMACEUTICAL PIPELINE/DEVICE BY MANUFACTURER, TYPE OF PRODUCT, INDICATIONS FOR USE, AND STAGE OF CLINICAL TESTING</i>	150
EXTREMITY REPAIR/REPLACEMENT	151
WRIGHT MEDICAL TECHNOLOGY	151
Simpliciti	151
Augment Bone Graft	151
CHAPTER 10 COMPANY DIRECTORY	153
TISSUE TYPING/DIAGNOSTICS	153
ABBOTT LABORATORIES	153
Business Overview	153
Products	153
BIORAD LABORATORIES	153
Business Overview	154
Products	154
CELERA CORP. (QUEST DIAGNOSTICS)	154
Business Overview	154
Products	154
DIAGAST	155
Business Overview	155
Products	155
HOLOGIC (GEN-PROBE)	155
Business Overview	156
Products	156
LIFE TECHNOLOGIES (PART OF THERMO FISHER SCIENTIFIC)	156
Business Overview	156
Products	156
LUMINEX CORP.	156
Business Overview	156
Products	157
ONE LAMBDA INC. (THERMO FISHER SCIENTIFIC)	157
Business Overview	157
Products	158
PROTEOME SCIENCES, PLC	158
Business Overview	158
Products	158
PRESERVATION SOLUTIONS (SOLID ORGAN/CELL/TISSUE)/ TRANSPORT SYSTEMS	159

TOPIC	PAGE NO.
BRIDGE TO LIFE LTD.	159
Business Overview	159
Products	159
CRYOLIFE INC.	159
Business Overview	159
Products	160
DR. F. KOHLER CHEMIE GMBH	160
Business Overview	160
Products	160
INSTITUT GEORGES LOPEZ (IGL)	160
Business Overview	161
Products	161
LIFEBLOOD MEDICAL INC./CELL PRESERVATION SOLUTIONS	161
Business Overview	161
Products	161
LIFELINE SCIENTIFIC	161
Business Overview	161
Products	162
ORGAN ASSIST	162
Business Overview	162
Products	162
ORGAN TRANSPORT SYSTEMS	162
Business Overview	162
Products	163
PARAGONIX TECHNOLOGIES	163
Business Overview	163
Products	163
PRESERVATION SOLUTIONS INC	163
Business Overview	164
Products	164
SANOFI (SEE GENZYME IN TRANSPLANT PHARMACEUTICALS)	164
TRANSMEDICS INC	164
Business Overview	164
Products	164
XVIVO PERFUSION AB	165
Business Overview	165
Products	165
TRANSPLANT PHARMACEUTICALS (IMMUNOSUPPRESSANTS, POST-TRANSPLANT PHARMACEUTICALS)	165
AMGEN INC.	165
Business Overview	166
Products	166
ASTELLAS PHARMA INC.	166
Business Overview	166
Products	166
BRISTOL-MYERS SQUIBB	166
Business Overview	167
Products	167

TOPIC	PAGE NO.
GENZYME (A SANOFI COMPANY)	167
Business Overview	167
Products	167
JANSSEN BIOTECH	168
Business Overview	168
Products	168
JANSSEN CILAG (SEE JANSSEN BIOTECH)	168
KIADIS PHARMA	168
Business Overview	168
Products	169
NOVARTIS INTERNATIONAL AG	169
Business Overview	169
Products	169
PFIZER INC.	169
Business Overview	170
Products	170
ROCHE PHARMACEUTICALS	170
Business Overview	170
Products	170
VELOXIS PHARMACEUTICALS (FORMERLY LIFECYCLE PHARMA A/S)	171
Business Overview	171
Products	171
MECHANICAL HEART IMPLANTS	171
ABIOMED	171
Business Overview	171
Products	172
BERLIN HEART GMBH	172
Business Overview	172
Products	172
HEARTWARE INTERNATIONAL INC.	172
Business Overview	172
Products	172
SYNCARDIA SYSTEMS INC.	173
Business Overview	173
Products	173
TERUMO HEART	173
Business Overview	173
Products	173
THORATEC CORP.	174
Business Overview	174
Products	174
HEART VALVES	174
BOSTON SCIENTIFIC	174
Business Overview	174
Products	174
EDWARDS LIFESCIENCES	175
Business Overview	175

TOPIC	PAGE NO.
Products	175
MEDTRONIC	175
Business Overview	175
Products	175
SORIN S.P.A.	176
Business Overview	176
Products	176
TERUMO CARDIOVASCULAR SYSTEMS CORP.	176
Business Overview	176
Products	176
JOINT/ORTHOPEDIC IMPLANTS	177
ALPHATEC SPINE	177
Business Overview	177
Products	177
ARTHREX INC.	177
Business Overview	177
Products	177
BIOMET, INC	178
Business Overview	178
Products	178
CONMED-LINVATEC CORP.	178
Business Overview	178
Products	179
DEPUY SYNTHES	179
Business Overview	179
Products	179
DJO SURGICAL	180
Business Overview	180
Products	180
EXACTECH	180
Business Overview	180
Products	180
INTEGRA LIFESCIENCE	181
Business Overview	181
Products	181
K2M GROUP HOLDINGS INC.	181
Business Overview	182
Products	182
LDR HOLDING CORP.	182
Business Overview	182
Products	182
NUVASIVE INC.	182
Business Overview	183
Products	183
ORTHOFIX INTERNATIONAL	183
Business Overview	183
Products	183

TOPIC	PAGE NO.
RTI BIOLOGICS	183
Business Overview	184
Products	184
SMITH & NEPHEW, PLC	185
Business Overview	185
Products	185
STRYKER	185
Business Overview	185
Products	186
TORNIER INC. (U.S.)	186
Business Overview	186
Products	186
W.L. GORE & ASSOCIATES	186
Business Overview	187
Products	187
WRIGHT MEDICAL TECHNOLOGY INC.	187
Business Overview	187
Products	187
ZIMMER HOLDINGS INC.	188
Business Overview	188
Products	188
TISSUE/BONE REGENERATIVE PRODUCTS	188
ACELITY (FORMERLY KINETIC CONCEPTS INC. AND LIFECELL)	188
Business Overview	189
Products	189
ALLOSOURCE	189
Business Overview	189
Products	189
BAXTER BIOSURGERY (BAXTER AND SYNOVIS SURGICAL INNOVATIONS)	190
Business Overview	190
Products	190
BIOMATLANTE	190
Business Overview	190
Products	191
BIOMIMETIC THERAPEUTICS INC. (SEE WRIGHT MEDICAL GROUP)	191
BIOTISSUE TECHNOLOGIES GMBH	191
Business Overview	191
Products	191
BONALIVE BIOMATERIALS LTD.	191
Business Overview	192
Products	192
CITAGENIX INC.	192
Business Overview	192
Products	192
COOK MEDICAL	193
Business Overview	193
Products	193

TOPIC	PAGE NO.
CURASAN AG	193
Business Overview	193
Products	194
DISCGENICS	194
Business Overview	194
Products	194
ETEX CORP.	194
Business Overview	195
Products	195
EXABONE GMBH	195
Business Overview	195
Products	195
FORTICELL BIOSCIENCE (FORMERLY ORTEC INTERNATIONAL, INC.)	196
Business Overview	196
Products	196
GLOBUS MEDICAL	196
Business Overview	196
Products	196
GRAFTYS	197
Business Overview	197
Products	197
DSM BIOMEDICAL (FORMERLY KENSEY NASH CORP.)	197
Business Overview	197
Products	197
MEDTRONIC INC.	198
Business Overview	198
Products	198
MOLNLYCKE HEALTH CARE	199
Business Overview	199
Products	199
MUSCULOSKELETAL TRANSPLANT FOUNDATION	199
Business Overview	199
Products	200
ORTHOVITA INC. (SEE STRYKER)	200
OSIRIS THERAPEUTICS INC.	200
Business Overview	200
Products	200
OSTEOGENICS BIOMEDICAL INC.	200
Business Overview	201
Products	201
TEI BIOSCIENCES	201
Business Overview	201
Products	201
TEKNIMED	202
Business Overview	202
Products	202
TETEC TISSUE ENGINEERING TECHNOLOGIES AG	202

TOPIC	PAGE NO.
Business Overview	202
Products	202
TIGENIX N.V.	203
Business Overview	203
Products	203
VIACYTE INC.	203
Business Overview	203
Products	203
CHAPTER 11 APPENDIX	205
<i>TABLE 67 DEFINITIONS</i>	205

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND DEVICES, THROUGH 2020 (\$ MILLIONS)	9
TABLE 1 TIMELINE OF ORGAN TRANSPLANTATION HISTORY, 1900-2012	12
TABLE 2 SELECTED TRANSPLANT INDUSTRY ACQUISITIONS, 2010-EARLY 2015 (\$ MILLIONS)	14
TABLE 3 U.S. ORGAN/TISSUE TRANSPLANTS: AVERAGE FIRST YEAR COST, ESTIMATED NUMBER OF PROCEDURES, AND VALUE BY TYPE OF ORGAN TRANSPLANT, 2011	20
TABLE 4 ORGAN DONATIONS IN EUROPE, BY TYPE, 2012-2013	24
TABLE 5 GLOBAL ACTIVITY IN ORGAN TRANSPLANTATION, 2012	27
TABLE 6 U.S. GRAFT SURVIVAL RATES, BY ORGAN AND YEARS (%)	29
TABLE 7 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*	37
TABLE 8 OVERVIEW OF MEDICARE IMMUNOSUPPRESSIVE DRUG COVERAGE	38
TABLE 9 TISSUE TYPING TECHNOLOGIES	42
TABLE 10 PROJECTED GLOBAL MARKET FOR TISSUE TYPING, THROUGH 2020 (\$ MILLIONS)	44
TABLE 11 PROJECTED GLOBAL TISSUE TYPING MARKET, BY REGION, THROUGH 2020 (\$ MILLIONS)	46
TABLE 12 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2007-2013	50
TABLE 13 PERCENT OF U.S. ORGAN DISCARDS, BY TYPE, 2012 (%)	50
TABLE 14 MEDIAN U.S. WAITLIST TIME FOR POTENTIAL RECIPIENTS, BY ORGAN AND NUMBER OF MONTHS, 2008 (NO. OF MONTHS)	53
TABLE 15 COLD ISCHEMIA TIME FOR TRANSPLANTED ORGANS (HOURS)	55
TABLE 16 PROJECTED GLOBAL MARKET FOR ORGAN PRESERVATION METHODS, THROUGH 2020 (\$ MILLIONS)	55
TABLE 17 OPTIMAL PRESERVATION SOLUTION DESIGN	56
TABLE 18 MAJOR ORGAN PRESERVATION SOLUTIONS	57
TABLE 19 PROJECTED GLOBAL MARKET FOR SOLID ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORTH COCKTAIL) BY GEOGRAPHIC REGION, THROUGH 2020 (\$ MILLIONS)	60
TABLE 20 ADVANTAGES AND DISADVANTAGES OF MACHINE PERFUSION	62
TABLE 21 PROJECTED GLOBAL MARKET FOR MACHINE PERFUSION /ORGAN TRANSPORT SYSTEMS, THROUGH 2020 (\$ MILLIONS)	63
TABLE 22 PROJECTED GLOBAL TISSUE GRAFTING MARKET, BY TISSUE TYPE THROUGH 2020 (\$ MILLIONS)	68
TABLE 23 PROJECTED GROWTH IN TISSUE MARKET REVENUES, BY REGION, THROUGH 2020 (\$ MILLIONS)	69
TABLE 24 CARTILAGE AND SOFT TISSUE BIOLOGICS AND BIOMATERIALS	71
TABLE 25 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, THROUGH 2020 (\$ MILLIONS)	72
TABLE 26 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, BY REGION, THROUGH 2020 (\$ MILLIONS)	72
TABLE 27 GLOBAL HEART VALVE MARKET, THROUGH 2020 (\$ MILLIONS)	75
TABLE 28 PROJECTED GLOBAL MARKET FOR HEART VALVES, BY REGION, THROUGH 2020 (\$ MILLIONS)	77
TABLE 29 PROJECTED GLOBAL GROWTH OF CORNEAL TRANSPLANT MARKET, THROUGH 2020* (\$ MILLIONS)	78
TABLE 30 PROJECTED GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION, THROUGH 2020 (\$ MILLIONS)	84

TABLE HEADING	PAGE NO.
TABLE 31 PROJECTED GLOBAL MARKET FOR ORTHOBIOLOGICAL PRODUCTS, THROUGH 2020* (\$ MILLIONS)	85
TABLE 32 HUMAN BONE PRODUCTS AND MARKETERS	86
TABLE 33 SYNTHETIC BONE-REPLACEMENT PRODUCTS AND MARKETERS	88
TABLE 34 PROJECTED GLOBAL GROWTH OF SKIN GRAFTS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 35 PROJECTED GLOBAL VASCULAR TISSUE TRANSPLANTATION MARKET, THROUGH 2020 (\$ MILLIONS)	91
TABLE 36 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS USED IN TRANSPLANTS, BY TYPE, THROUGH 2020 (\$ MILLIONS)	95
TABLE 37 IMMUNOSUPPRESSANT DRUGS APPROVED IN THE U.S., THE EU, AND JAPAN, THROUGH 2014	97
TABLE 38 IMMUNOSUPPRESSANTS BY DRUG CLASS, GENERIC NAME, BRAND NAME, AND MANUFACTURER	97
TABLE 39 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 40 GLOBAL MARKET FOR ANTI-PROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 (\$ MILLIONS)	101
TABLE 41 PROJECTED GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 (\$ MILLIONS)	102
TABLE 42 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION	103
TABLE 43 PROJECTED GLOBAL MARKET FOR POLYCLONAL ANTIBODY PRODUCTS, THROUGH 2020 (\$ MILLIONS)	104
TABLE 44 PROJECTED GLOBAL MARKET FOR T-CELL COSTIMULATION BLOCKERS, THROUGH 2020 (\$ MILLIONS)	105
TABLE 45 IMMUNOSUPPRESSANT USE FOR INDUCTION BY ORGAN IN U.S., 2012* (%)	107
TABLE 46 IMMUNOSUPPRESSANT USE FOR MAINTENANCE (UP TO 2 YEARS POST-TRANSPLANT) BY ORGAN, 2010* (%)	108
TABLE 47 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, THROUGH 2020 (\$ MILLIONS)	110
TABLE 48 COMMON ANTI-INFECTIVE AND IMMUNOSUPPRESSANT AGENTS AND INTERACTIONS, 2012*	112
TABLE 49 POST-TRANSPLANT INFECTIONS BY TYPE OF TRANSPLANT, WITH COMMON TIME FRAMES FOR INFECTION	114
TABLE 50 RECOMMENDED POST-TRANSPLANT CARE, 2012	116
TABLE 51 PROJECTED GLOBAL MARKET FOR TRANSPLANTATION ALTERNATIVE DEVICES, THROUGH 2020 (\$ MILLIONS)	121
TABLE 52 GLOBAL MARKET FOR ARTIFICIAL HEART DEVICES, THROUGH 2020 (\$ MILLIONS)	123
TABLE 53 GLOBAL MARKET FOR TOTAL ARTIFICIAL HEARTS, THROUGH 2020 (\$ MILLIONS)	124
TABLE 54 GLOBAL MARKET FOR VADS, THROUGH 2020 (\$ MILLIONS)	124
TABLE 55 SELECTED GLOBAL COMMERCIAL OPPORTUNITIES FOR NEW DEVICES IN THE FUTURE	125
TABLE 56 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC DEVICES USED IN TRANSPLANTATION, THROUGH 2020 (\$ MILLIONS)	126
TABLE 57 PROJECTED GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	129
TABLE 58 PROJECTED GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	130

TABLE HEADING	PAGE NO.
TABLE 59 PROJECTED GLOBAL MARKET FOR SPINAL RECONSTRUCTIVE PRODUCTS, THROUGH 2020 (\$ MILLIONS)	131
TABLE 60 PROJECTED GLOBAL MARKET FOR EXTREMITY REPAIR/REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	132
TABLE 61 THERAPEUTIC INDICATIONS FOR PTK	133
TABLE 62 INDICATIONS FOR BIOARTIFICIAL LIVER TRANSPLANTATION	137
TABLE 63 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC AND CARDIAC ALTERNATIVE THERAPIES, BY REGION, THROUGH 2020 (\$ MILLIONS)	139
TABLE 64 TYPES OF REGENERATIVE CELLULAR THERAPIES	145
TABLE 65 SELECTED IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT, 2015	149
TABLE 66 PHARMACEUTICAL PIPELINE/DEVICE BY MANUFACTURER, TYPE OF PRODUCT, INDICATIONS FOR USE, AND STAGE OF CLINICAL TESTING	150
TABLE 67 DEFINITIONS	205

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE PROJECTED GLOBAL MARKET SHARE OF TRANSPLANTATION PRODUCTS AND DEVICES, 2015 AND 2020 (%)	10
FIGURE 1 GLOBAL MARKET SHARES IN TISSUE TYPING TECHNOLOGIES BY MARKET LEADER, 2014 (%)	45
FIGURE 2 GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS 2013 (%)	61
FIGURE 3 GLOBAL TISSUE MARKET SHARES BY REGION, 2015 AND 2020 (%)	69
FIGURE 4 GLOBAL SOFT TISSUE MARKET, BY REGION, IN 2015 AND 2020 (%)	73
FIGURE 5 LEADING HEART VALVE SUPPLIERS, 2014 (%)	76
FIGURE 6 PROJECTED GLOBAL MARKET SHARES OF IMMUNOSUPPRESSIVES BY TYPE, THROUGH 2020 (%)	96
FIGURE 7 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, 2015 AND 2020 (%)	110
FIGURE 8 GLOBAL MARKET FOR ORTHOPEDIC DEVICES, BY TYPE, 2015 AND 2020 (%)	126
FIGURE 9 ORTHOPEDIC REPLACEMENT DEVICE MARKET, BY COMPANY MARKET SHARE, 2014 (%)	128
FIGURE 10 GLOBAL MARKET SHARES OF THE SPINAL RECONSTRUCTION MARKET BY COMPANY, 2013 (%)	131
FIGURE 11 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC IMPLANT PRODUCTS, BY REGION, 2015 AND 2020 (%)	139